Quantcast
Connect with us

Stem cells could regenerate organs – but only if the body won’t reject them

Published

on

Many of the most common diseases, like heart failure, liver failure, Type 1 diabetes and Parkinson’s disease, occur when cells or whole organs fail to do their job. Wouldn’t it be fantastic if it were possible to replace cells in these defunct organs? That is exactly what physician-scientists in the field of regenerative medicine are trying to do.

I am a surgeon and stem cell scientist and am interested in regenerating failing organs with stem cells – because for many diseases we don’t have good treatment options yet.

ADVERTISEMENT

In a recent paper, my colleagues and I figured out why stem cells derived from a patient’s own tissue are sometimes rejected by their own immune systems. We also developed a solution that we think may solve the problem: stem cells that are stripped of their immune features and can’t trigger rejection.

The search for the ideal starter cell

A few years ago a breakthrough occurred that many scientists believed would help fast-track the goal of regenerating organs. That was the identification of proteins that turn on genes that allowed researchers to reprogram adult cells. These proteins transformed cells back into their embryonic-like stem cell state. This gives them the capacity to turn into almost any cell type – like liver or heart or any other cell of interest.

These stem cells can theoretically be used as an inexhaustible source for cells. Scientists believed these cell products could be used to restore the functions of organs and treat diseases. However, regenerating cells and organs from a patient’s own cells and then returning them to that same patient turned out to be trickier than expected.

Researchers are still debating what is the ideal starting cell type for regenerative medicine. The cells required for these therapies can be grown in bioreactors in the lab. But for cell therapies to succeed, the biggest hurdle we have to overcome is immune rejection.

Like transplanted organs, transplanted cells are susceptible to attacks by the recipient’s immune system. Any cells generated from another individual have different proteins on their surface, called tissue antigens, that tag them as “foreign.”

ADVERTISEMENT

Once tagged, white blood cells, which defend the body against bacteria, viruses and foreign tissue, target these therapeutic cells for destruction. Physicians use high-dose immunosuppressive drugs to silence this immune response so that patients can tolerate a transplanted organ. But these drugs have significant side effects.

To create cells for use in regenerative medicine, scientists envision large-scale collections of stem cells with diverse characteristics and specific tissue antigens. Then just as blood types can be matched, these cataloged stem cells could be matched to the recipient to avoid the patient’s immune system from rejecting these new cells.

One day, hospitals may have enough cell lines to match patients with stem cells based on tissue types. Whether enough cell lines can be banked to serve the wider patient population and whether this strategy will prevent immune responses is yet to be seen.

ADVERTISEMENT

Adult cells are removed from patients, transformed into so-called induced pluripotent stem cells and then, using various chemicals, the cells are made to differentiate into different tissue types. Ideally these are then transplanted into the same patient to fix their damaged tissues.
metamorworks/Shutterstock.com

Hurdles for using a patient’s own stem cells

Stem cells generated from a patient’s own cells – called autologous stem cells – are currently believed to be the most promising strategy for circumventing immune rejection. Autologous stem cells are generated directly from the patient seeking treatment and need to be differentiated into the cell type that needs to be replaced. Since the cells carry the same tissue antigens as the patient, they are tagged as “self,” and immunologists believe these cells are accepted by the immune system.

However, this notion may not be correct. In a previous study, our lab had revealed that minor genetic mutations in the DNA carried by a special part of the cell’s DNA, the mitochondrial DNA, can trigger an immune response.

ADVERTISEMENT

Mitochondria are small structures inside cells that carry their own set of genes that are responsible for generating energy for the cell. Because every cell has many mitochondria, they carry many copies of the mitochondrial DNA. Spontaneous changes in mitochondrial genes, called mutations, alter the shape of the proteins they encode. These mutated proteins, which we call “neoantigens,” re-tag the cells as “foreign,” alert the immune system and target the stem cells for destruction.

Cells that lack immune features may be the solution

Our latest study reveals that neoantigens can spontaneously occur in a patient’s own cells. This renders them susceptible to rejection when used as part of stem cell-based treatment. We showed in mice and humans that minor changes in the mitochondrial DNA can occur when the patient’s cells are being reprogrammed into stem cells so that they can produce different types of cells. This can also happen while the cells are multiplying in plates or bioreactors outside of the body, giving rise to neoantigens.

The likelihood of neoantigens arising increases with the time it takes to manufacture a particular type of cell. If white blood cells recognize neoantigens after injecting the cells back into the animal or human, they may trigger a strong immune response leading to tissue rejection.

ADVERTISEMENT

Neoantigens can thus jeopardize the whole strategy of autologous cell transplantation. So to use this form of cell transplantation, it may be necessary to test all cell products for mutations in the mitochondrial DNA.

To dodge the immune system and make regenerative stem cell therapies widely available to the general public, our lab aims to engineer stem cells lacking any immune features.

Modern gene editing tools now allow us to make very specific edits and create engineered cell products without any tissue type tags. We recently published our early success with both edited mouse and human stem cells, which survived after transplantation into different mouse models with different tissue types. This was the first report of “universal cells” that completely circumvented rejection by a foreign immune system. We believe this concept could lead to the manufacturing of universal cell products for all patients and has the potential to transform health care.

[ You’re smart and curious about the world. So are The Conversation’s authors and editors. You can read us daily by subscribing to our newsletter. ]The Conversation

ADVERTISEMENT

Tobias Deuse, Professor of Surgery, University of California, San Francisco

This article is republished from The Conversation under a Creative Commons license. Read the original article.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Lev Parnas has Trump ‘unnerved’: ex-FBI official says the president doesn’t know what he ‘has up his sleeve’

Published

on

President Donald Trump is "very nervous" about what Lev Parnas may have on him, a former top FBI official suggested on MSNBC on Friday.

Former FBI Assistant Director for Counterintelligence was interviewed by MSNBC's Peter Alexander.

The host played clips of Trump denying any relationship with Parnas.

"Well, I don't know him, I don't know Lev Parnas, other than I guess I had pictures taken -- which I do with thousands of people," Trump argued. "I don't know him at all, don't know what he's about, don't where he comes from. I can tell you this -- I don't know him. I don't believe I've ever spoken to him. I don't believe I've ever spoken to him."

Continue Reading

Breaking Banner

Trump is now feuding with Iran’s Supreme Leader on Twitter: ‘Make Iran Great Again!’

Published

on

President Donald Trump is now replying directly to Iran Supreme Leader Ayatollah Ali Khamenei on Twitter.

I Friday, Khamenei tweeted a screenshot of a Trump tweet, with a message of his own.

"The villainous US govt repeatedly says that they are standing by the Iranian ppl. They lie. If you are standing by the Iranian ppl, it is only to stab them in the heart with your venomous daggers," Khamenei posted.

"Of course, you have so far failed to do so, & you will certainly continue to fail," he added.

https://twitter.com/khamenei_ir/status/1218141834842660864

Trump retweeted the message, adding his own argument.

Continue Reading
 

Facebook

‘Contempt of Congress is illegal’ declared one of Trump’s newest attorneys – just days before the House voted to impeach

Published

on

One of the lesser-known names on the new list of lawyers President Donald Trump approved to defend him during the Senate impeachment trial delivered a damning remark last month – damning for President Trump, that is.

"Contempt of Congress is illegal," said Robert Ray, who served as the final Whitewater independent counsel after Ken Starr.

The Washington Post's Paul Waldman and Greg Sargent report Ray made the stunning remark – one of the Articles of Impeachment essentially is contempt of Congress, or technically, obstruction of Congress – to The Daily Signal, a right wing website run by the conservative Heritage Foundation.

Continue Reading
 
 
Help Raw Story Uncover Injustice. Join Raw Story Investigates for $1 and go ad-free.
close-image